Compare State Street SPDR S&P Biotech ETF (XBI) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs State Street SPDR S&P Homebuilders ETF — how do they compare? State Street SPDR S&P Biotech ETF trades at $159.65, while State Street SPDR S&P Homebuilders ETF trades at $108.31. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals.
| XBI | XHB | |
|---|---|---|
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $164.28 | $121.36 |
52-Week Low | $88.79 | $94.86 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
XHB trades at $108.35 with a slight 0.1% daily gain, showing bullish technical momentum with strong moving average support. The ETF benefits from positive housing market developments including new home sales growth and supportive legislation, though mixed economic data creates uncertainty. Technical indicators show overall bullish sentiment with 14 buy signals versus 3 sell signals.
The outlook remains cautiously optimistic as housing affordability legislation and seasonal demand provide tailwinds, but high mortgage rates and record home prices pose headwinds. Key risks include interest rate sensitivity and economic volatility, while institutional positioning suggests selective confidence in the homebuilding sector's recovery prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
